ClinicalTrials.gg

Program

GXV-813

In Novartis's pipeline, M4 agonist. Its studies are mostly in Schizophrenia, led by Novartis.

Furthest: phase 2, since Mar 9, 20261 company-led study, 1 open or runningNext primary completion: Jul 29, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 2since Mar 9, 2026Mar 9, 2026Jul 29, 2027phase 2 · NCT07467993
  • Named in Novartis’s own pipeline as GXV813, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2026First study: phase 2 study in SchizophreniaFirst studyNCT07467993 · 142 planned · United States, Bulgaria

Ahead

  1. Jul 29, 2027Primary completion: phase 2 study in SchizophreniaNCT07467993

TargetBeta

“M4 agonist”the company's pipeline, read by Claude · source

Other programs on CHRM4

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487
xanomelineruleBristol-Myers Squibbphase 438
emraclidineAbbViephase 218
ABBV-1042AbbViephase 11
BMS-986521Bristol-Myers Squibbphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07467993Schizophrenia · United States, Bulgaria2RecruitingJul 29, 2027142

How it is read

Names in the registry

  • “GXV813”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.